Skip to main content
. Author manuscript; available in PMC: 2022 Sep 28.
Published in final edited form as: J Neurooncol. 2010 Jun 6;101(2):257–265. doi: 10.1007/s11060-010-0252-3

Table 3.

Selected HIV-related characteristics of HIV positive patients with PCNSL

Characteristics n+/n (%)
HAART at diagnosis 13/37 (35)
HAART added after PCNSL diagnosis 17/24 (71)
CD4 at diagnosis of PCNSL < 200 33/35 (92)
CD4 at diagnosis of PCNSL < 50 23/35 (66)
CD4 at PCNSLa 56 ± 14 (2-374)
CD4 at HIV diagnosisa 75 ± 13 (2-247)
Interval between HIV and PCNSL diagnoses (mos)a 55.2 ± 8.8 (0-184.9)
a

Mean ± SE (range)

HAART highly-active antiretroviral treatment, PCNSL primary CNS lymphoma